StockNews.com Initiates Coverage on DBV Technologies (NASDAQ:DBVT)

StockNews.com began coverage on shares of DBV Technologies (NASDAQ:DBVT - Free Report) in a research note released on Saturday. The firm issued a hold rating on the stock.

A number of other equities analysts have also recently commented on DBVT. JMP Securities reiterated a "market outperform" rating and issued a $25.00 target price on shares of DBV Technologies in a report on Tuesday, September 24th. HC Wainwright raised their price target on DBV Technologies from $25.00 to $35.00 and gave the stock a "buy" rating in a research note on Thursday, October 24th.

DBV Technologies Stock Up 27.2 %

NASDAQ DBVT traded up $0.84 during trading on Friday, hitting $3.90. 126,875 shares of the stock traded hands, compared to its average volume of 45,795. The company has a market capitalization of $75.27 million, a P/E ratio of -0.87 and a beta of 0.66. The firm has a 50-day simple moving average of $3.42 and a 200-day simple moving average of $4.17. DBV Technologies has a 12-month low of $2.20 and a 12-month high of $10.70.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.